Vaxcyte Inc
vaxcyte.comWhat Do They Do?
Develops vaccines to prevent bacterial diseases in adults and children, using a cell-free method to make vaccine proteins.
10-K for FY2025, filed Feb 24, 2026We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of…View ↗
We carefully select our target disease areas and vaccine candidates based on the following criteria: areas of significant unmet medical…View ↗
PCV candidates that we believe are among the broadest-spectrum PCV candidates currently in development, targeting the approximately $8…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Feb 24, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
−$284.3MView ↗
- ▲ +71% (Loss)
- vs −$166.6M in Q2 FY2025
Pneumococcal program focus
The earlier lead candidate for adults and children has given way to a broader candidate being developed for both groups, while the earlier lead is now described for infants.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 24, 2026Our lead vaccine candidate, VAX-24, is a 24-valent, broad-spectrum investigational PCV being developed for the prevention of IPD. VAX-24 is…View ↗
PCV candidates that we believe are among the broadest-spectrum PCV candidates currently in development, targeting the approximately $8…View ↗
Shigella vaccine work
The Shigella vaccine program has been paused before clinical development, while the company preserves the option to advance it later.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 24, 2026VAX-GI, a new vaccine program designed to prevent Shigella, a bacterial illness that affects an estimated 188 million people worldwide each…View ↗
Post-dose 4, all VAX-24 doses met our target Phase 2 IgG GMR point estimate of >0.6 for the three highest circulating serotypes contained…View ↗
Who Do They Compete With?
Competes with Pfizer, Merck, GSK, Sanofi, SK bioscience, Moderna, VaxForm, BioMVis, Valneva, and LimmaTech
10-K for FY2025, filed Feb 24, 2026In recent history, the global vaccine market has been highly concentrated among a small number of multinational pharmaceutical companies.…View ↗
Loading...
